A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. LBA4-LBA4 ◽  
Author(s):  
N. Wolmark ◽  
G. Yothers ◽  
M. J. O'Connell ◽  
S. Sharif ◽  
J. N. Atkins ◽  
...  
Keyword(s):  
Annual Meeting ◽  
Clinical Oncology ◽  
Stage Ii ◽  
Phase Iii ◽  
Phase Iii Trial ◽  
Carcinoma Of The Colon ◽  
Final Text ◽  
Financial Relationships

LBA4 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. No significant financial relationships to disclose.

AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA5002-LBA5002 ◽  
Author(s):  
Eric Pujade-Lauraine ◽  
Felix Hilpert ◽  
Béatrice Weber ◽  
Alexander Reuss ◽  
Andres Poveda ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Recurrent Ovarian Cancer ◽  
Phase Iii ◽  
Daily News ◽  
Phase Iii Trial ◽  
Online Supplement ◽  
Final Text

LBA5002^ The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Saturday, June 2, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.

Randomized phase III trial of imatinib (IM) rechallenge versus placebo in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) after failure of at least both IM and sunitinib (SU): Right study.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. LBA10502-LBA10502
Author(s):  
Yoon-Koo Kang ◽  
Min-Hee Ryu ◽  
Baek-Yeol Ryoo ◽  
Hyun Jin Kim ◽  
Jong Jin Lee ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumor ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Stromal Tumor ◽  
Phase Iii ◽  
Daily News ◽  
Phase Iii Trial ◽  
Online Supplement ◽  
Final Text

LBA10502 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Monday, June, 3, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA10008-LBA10008 ◽  
Author(s):  
George D. Demetri ◽  
Peter Reichardt ◽  
Yoon-Koo Kang ◽  
Jean-Yves Blay ◽  
Heikki Joensuu ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumor ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Prior Treatment ◽  
Stromal Tumor ◽  
Phase Iii ◽  
Daily News ◽  
Phase Iii Trial ◽  
Online Supplement ◽  
Final Text

LBA10008 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

ESPAC-3(v2): A multicenter, international, open-label, randomized controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. LBA4505-LBA4505
Author(s):  
J. Neoptolemos ◽  
M. Büchler ◽  
D. D. Stocken ◽  
P. Ghaneh ◽  
D. Smith ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Folinic Acid ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Phase Iii ◽  
Ductal Adenocarcinoma ◽  
Open Label ◽  
Phase Iii Trial ◽  
Randomized Controlled ◽  
Final Text

LBA4505 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. [Table: see text]

Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 4-4 ◽  
Author(s):  
Maha Hussain ◽  
Catherine M. Tangen ◽  
Celestia S. Higano ◽  
E. David Crawford ◽  
Glenn Liu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Metastatic Prostate Cancer ◽  
Phase Iii ◽  
Daily News ◽  
Phase Iii Trial ◽  
Online Supplement ◽  
Hormone Sensitive ◽  
Final Text

4 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. LBA2010-LBA2010 ◽  
Author(s):  
Erik P. Sulman ◽  
Minhee Won ◽  
Deborah T. Blumenthal ◽  
Michael A. Vogelbaum ◽  
Howard Colman ◽  
...  
Keyword(s):  
Annual Meeting ◽  
Clinical Oncology ◽  
Phase Iii ◽  
Newly Diagnosed ◽  
Predictors Of Outcome ◽  
Daily News ◽  
Phase Iii Trial ◽  
Online Supplement ◽  
Newly Diagnosed Glioblastoma ◽  
Final Text

LBA2010 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Sunday, June, 2, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

SCORAD III: Randomized noninferiority phase III trial of single-dose radiotherapy (RT) compared to multifraction RT in patients (pts) with metastatic spinal canal compression (SCC).

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. LBA10004-LBA10004 ◽  
Author(s):  
Peter Hoskin ◽  
Vivek Misra ◽  
Kirsten Hopkins ◽  
Tanya Holt ◽  
Gillian Brown ◽  
...  
Keyword(s):  
Single Dose ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Spinal Canal ◽  
Phase Iii ◽  
Daily News ◽  
Phase Iii Trial ◽  
Online Supplement ◽  
Final Text

LBA10004 The full, final text of this abstract will be available at abstracts.asco.org at 2:00 PM (EDT) on Friday, June 2, 2017, and in the Annual Meeting Proceedings online supplement to the June 20, 2017, issue of the Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.

A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. LBA3500-LBA3500 ◽  
Author(s):  
N. Wolmark ◽  
S. Wieand ◽  
J. P. Kuebler ◽  
L. Colangelo ◽  
R. E. Smith
Keyword(s):  
Stage Ii ◽  
Phase Iii ◽  
Phase Iii Trial ◽  
Carcinoma Of The Colon

Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. LBA9084-LBA9084
Author(s):  
M. A. Henderson ◽  
B. Burmeister ◽  
J. F. Thompson ◽  
J. Di Iulio ◽  
R. Fisher ◽  
...  
Keyword(s):  
Lymph Node ◽  
Randomized Trial ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Adjuvant Radiotherapy ◽  
Regional Lymph Node ◽  
Field Control ◽  
Melanoma Patients ◽  
Final Text ◽  
Financial Relationships

LBA9084 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. No significant financial relationships to disclose.

Carboplatin plus paclitaxel versus carboplatin plus stealth liposomal doxorubicin in patients with advanced ovarian cancer (AOC): Final results of the MITO-2 randomized multicenter trial

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. LBA5508-LBA5508
Author(s):  
S. Pignata ◽  
G. Scambia ◽  
A. Savarese ◽  
R. Sorio ◽  
E. Breda ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Liposomal Doxorubicin ◽  
Advanced Ovarian Cancer ◽  
Multicenter Trial ◽  
Final Text ◽  
Financial Relationships

LBA5508 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document